Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BDR-731
- Development stage
- Preclinical
- Lead developer
- BioDrone Therapeutics
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
BDR-731 is a **preclinical cardiovascular therapeutic candidate** from **BioDrone Therapeutics** built on the company's **cell-derived vesicle platform**. The program is described as an **MSC-derived cell vesicle** therapy, placing it within the extracellular vesicle and regenerative cell-therapy space rather than as a conventional small molecule or antibody. Based on the company pipeline context, BDR-731 is being developed for **cardiovascular disease** and is intended to use mesenchymal stem cell-derived vesicles to deliver reparative and immunomodulatory biological cargo to injured cardiovascular tissue, with the goal of supporting tissue repair and reducing inflammation. No specific molecular target, administration route, dosage form, or clinical-stage efficacy data have been publicly disclosed in the provided sources.
- Other names
- BioDrone Therapeutics BDR-731BDR-731 CDVBDR731 CDVBDR 731 CDVBDR-731 MSC-derived cell vesicleBDR731 MSC-derived cell vesicleBDR 731 MSC-derived cell vesicle
Beyond the preview
Go deeper on BDR-731.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BDR-731.